The successful use of eculizumab for treatment of thrombotic microangiopathy in pediatric acute SARSCoV2 infection and multisystem inflammatory syndrome in children

Haematologica. 2022 Oct 1;107(10):2517-2522. doi: 10.3324/haematol.2022.280603.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • COVID-19 Drug Treatment*
  • COVID-19* / complications
  • Child
  • Complement Inactivating Agents / therapeutic use
  • Humans
  • Infections*
  • RNA, Viral
  • SARS-CoV-2
  • Systemic Inflammatory Response Syndrome
  • Thrombotic Microangiopathies* / diagnosis
  • Thrombotic Microangiopathies* / drug therapy
  • Thrombotic Microangiopathies* / etiology

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement Inactivating Agents
  • RNA, Viral
  • eculizumab

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related

Grants and funding

Funding: GM receives research funding from Astellas Inc and SymBio Pharmaceuticals Limited. MH receives research funding from Incyte. AS is the site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (clinicaltrials gov. Identifier: NCT03745287) and Novartis (clinicaltrials gov. Identifier: NCT04443907). The industry sponsors provide funding for the clinical trial, which includes salary support paid to AS institution. AS has received consultant fee from Spotlight Therapeutics, Medexus Inc. and Vertex Pharmaceuticals. AS has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education. JH receives research funding from Global Blood Therapeutics and consultancy fees from Global Blood Therapeutics, Forma Therapeutics and bluebird bio. SB receives grant support from the American Society of Hematology.